Navigation Links
Clinical Experience With Peregrine's Anti-Cancer Agent Bavituximab Presented at Leading Symposium on Anti-Angiogenic Agents
Date:2/8/2008

atients and the two other trials are expected to begin soon. Bavituximab is also in clinical trials in the U.S. in patients co-infected with HCV and HIV.

Dr. Stopeck's presentation, "Phase I Clinical Studies of the Anti-Tumor Vasculature Antibody, Bavituximab," is part of the Angio 2008 session on Early Drug Development/Clinical Trial Results being held from 8:00 am to 12:00 pm PST at the 10th Annual International Symposium on Anti-Angiogenic Agents at the Hyatt Regency Hotel in La Jolla, CA.

About Peregrine Pharmaceuticals

Peregrine Pharmaceuticals, Inc. is a biopharmaceutical company with a portfolio of innovative product candidates in clinical trials for the treatment of cancer and hepatitis C virus (HCV) infection. The company is pursuing three separate clinical programs in cancer and HCV infection with its lead product candidates bavituximab and Cotara(R). Peregrine also has in-house manufacturing capabilities through its wholly owned subsidiary Avid Bioservices, Inc. (http://www.avidbio.com), which provides development and bio-manufacturing services for both Peregrine and outside customers. Additional information about Peregrine can be found at http://www.peregrineinc.com.

Safe Harbor Statement: Statements in this press release which are not purely historical, including statements regarding Peregrine Pharmaceuticals' intentions, hopes, beliefs, expectations, representations, projections, plans or predictions of the future are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. The forward-looking statements involve risks and uncertainties including, but not limited to, the risk that results of future clinical trials will not correlate with the results of earlier phase I trials and preclinical studies. It is important to note that the company's actual results could differ materi
'/>"/>

SOURCE Peregrine Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Ardea Biosciences Presents Preclinical Data Demonstrating Favorable Resistance Profiles for Non-Nucleoside Reverse Transcriptase Inhibitors for the Treatment of Human Immunodeficiency Virus
2. IDX899 Demonstrates Rapid and Profound Inhibition of HIV Replication in a Phase I/II Clinical Trial in Treatment-Naive HIV-Infected Patients
3. Rapid Growth of Asia-Pacific Clinical Trials Market Focus of New CenterWatch Report
4. Northwestern Offers Clinical Research and Regulatory Administration Graduate Certificate Program
5. Multiple Dose Clinical Trial of TorreyPines Therapeutics Tezampanel Demonstrates Compound is Safe and Well-Tolerated
6. Alexza Initiates AZ-007 (Staccato(R) Zaleplon) Phase 1 Clinical Trial and Updates Clinical Pipeline Development Status
7. PTC Therapeutics Announces Publication of Preclinical Data in PNAS
8. Successful Clinical Trials and Launch in New Zealand Spurs Phloe to Enter US Market
9. Aung FootHealth Clinics & Advanced Wound Care Center Enrolling Patients With Chronic Diabetic Foot Ulcers for Matrix Clinical Trial
10. IDM Pharma Announces Phase 3 Mifamurtide (L-MTP-PE) Study Demonstrating Improved Survival Published in the Journal of Clinical Oncology
11. NanoBio Corporation Presents Preclinical and Interim Clinical Data on Topical Treatments for Herpes Labialis and Onychomycosis at AAD 2008
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/19/2014)... 2014 Today, iHealth Lab Inc. announced it has ... for its first institutional round of funding. The strategic ... reach, accelerate growth and innovation, and invest in additional ... Xiaomi Ventures will join iHealth,s board of directors, bringing ... ecommerce. "We are very pleased to have ...
(Date:9/19/2014)... DALLAS , September 19, 2014 ... Equipment Market by Equipment (Cryotherapy, Heat, therapy, Hydrotherapy), ... End Users (Hospitals), Advanced technologies - Global Forecast ... Market is poised to reach $19,786.3 Million by ... CAGR of 6.8% from 2014 to 2019. ...
(Date:9/19/2014)... WASHINGTON , Sept. 19, 2014 The ... that Drive Medical Design and Manufacturing has joined the ... its CEO Harvey Diamond have been actively ... year history, as it has quickly grown into a ... corporate partners like Drive allows AAHomecare to increase efforts ...
Breaking Medicine Technology:iHealth Raises $25 Million to Fuel Growth and Global Market Share 2Physiotherapy Equipment Market Worth $19,786.3 Million by 2019 2Physiotherapy Equipment Market Worth $19,786.3 Million by 2019 3Physiotherapy Equipment Market Worth $19,786.3 Million by 2019 4Drive Medical Design & Manufacturing Joins AAHomecare Corporate Partner Program 2
... Young Innovations, Inc. (Nasdaq: YDNT ) today announced that it will broadcast ... call on Wednesday, July 21, 2010 at 11:00 a.m. Central ... InterCall at http://tinyurl.com/yiq210 . Access to the live audio broadcast will also ... , , ...
... Ill. , July 14 RoundTable Healthcare ... the health-care industry, announced today that it has entered ... portfolio companies, Bioniche Pharma Holdings Limited ("Bioniche Pharma") to ... pharmaceutical company, for $550 million in cash. ...
Cached Medicine Technology:Young Innovations, Inc. Provides 2nd Quarter Conference Call Details 2RoundTable Healthcare Partners Announces Sale of Bioniche Pharma Holdings Limited to Mylan Inc. 2RoundTable Healthcare Partners Announces Sale of Bioniche Pharma Holdings Limited to Mylan Inc. 3
(Date:9/22/2014)... CA (PRWEB) September 22, 2014 ... course from Winter & Alvin has just been ... excitement throughout the personal development community. The media ... attention of HonestyFirstReviews.com's Tiffany Hendricks prompting an investigative ... topic of great interest for many entrepreneurs and ...
(Date:9/22/2014)... 22, 2014 QueenBeeTickets.com has the largest ... larger with discount Stevie Wonder tickets. The phenomenal singer/songwriter ... Tour,” and 11 cities have been put on the ... , Click Here to view the selection ... , Stevie Wonder ticket sales are bound to be ...
(Date:9/22/2014)... AttorneyOne.com, a recognized authority on law, update the ... on Twix . , Mars Chocolate North America announced ... Stand Up Pouch with specific code date are recalled due ... is that Twix Unwrapped Bites 7 oz. Stand Up Pouch ... writing them on the ingredient label. , In case ...
(Date:9/22/2014)... 2014 The Center for Health ... ERC as one of the NorthCoast 99 ... places to work for top talent. This award recognizes ... maintain great workplaces that support the attraction, retention and ... staffing and workforce, development and training, compensation and rewards, ...
(Date:9/22/2014)... The Ruby Report was launched by the ... Conference in Louisville, Kentucky. This release followed the May ... reception attended by 60 people from the local area. ... gained while conducting her research, what drove her to ... and what she believes companies can do to be ...
Breaking Medicine News(10 mins):Health News:"The Millionaire's Brain" - A Review Examining Winter & Alvin's Training Course Released 2Health News:Discount Stevie Wonder Tickets: QueenBeeTickets.com Delights Customers with Discounted Concert Tickets for Stevie Wonder’s 11-City Tour Set to Kick off in November 2Health News:Mars Chocolate North America Recalls Twix Bites: AttorneyOne Monitors and Keeps Consumers Informed 2Health News:The Center for Health Affairs Named to 2014 NorthCoast 99 List 2Health News:The Center for Health Affairs Named to 2014 NorthCoast 99 List 3Health News:Ruby Report Book Launch Reveals Critical Insights on Gender Intelligence 2
... 10 Caliper Life Sciences, Inc. (Nasdaq: ... at the Cowen and Company 29th Annual Health ... on Tuesday, March 17 at 10:15 a.m. ET. ... will be providing an update on the company,s ...
... Report Finds Public Health Programs At Risk During Economic ... and the Robert Wood Johnson Foundation (RWJF) today released ... received less funding from the federal government than Northeastern ... for disease prevention programs, which can amount to millions ...
... Designed to Optimize Treatment of Patients with Coronary ... Abbott ( NYSE: ABT ) today announced ... a next-generation balloon dilatation catheter with high-pressure capability ... coronary artery disease (CAD) during angioplasty procedures. VOYAGER ...
... 10 Johnson & Johnson will participate in the ... Monday, March 16th at the Boston Marriott Copley Place ... President, Finance and Chief Financial Officer, will represent the ... Time). The webcast will be available to investors and ...
... 10 The Kavli Foundation has announced the appointment ... - only the second president since the Foundation was ... Foundation,s President in late April of this year.Dr. Conn ... acclaimed scientist whose research is focused on plasma physics ...
... in the March issue of the Journal of ... transplantation should be used with caution in patients older ... with high rates of mortality after one year in ... the gold-standard treatment for a variety of end-stage lung ...
Cached Medicine News:Health News:Midwestern and Southern States Receive Least Federal Funding for Disease Prevention 2Health News:Midwestern and Southern States Receive Least Federal Funding for Disease Prevention 3Health News:Midwestern and Southern States Receive Least Federal Funding for Disease Prevention 4Health News:Abbott Launches VOYAGER(TM) NC Coronary Balloon Catheter 2Health News:Abbott Launches VOYAGER(TM) NC Coronary Balloon Catheter 3Health News:Abbott Launches VOYAGER(TM) NC Coronary Balloon Catheter 4Health News:Abbott Launches VOYAGER(TM) NC Coronary Balloon Catheter 5Health News:Dr. Robert W. Conn Named President of The Kavli Foundation 2Health News:Dr. Robert W. Conn Named President of The Kavli Foundation 3Health News:Dr. Robert W. Conn Named President of The Kavli Foundation 4Health News:Journal of American College of Surgeons finds lung transplantation should be used in older patients 2
... enzyme immunoassay kit for the quantitative ... in serum. Enzyme immunoassay (EIA) permits ... protein hormones in body fluids and ... and specific assay. This enzyme immunoassay ...
SHIONORIA BNP,is a reagent used in the measurement of blood BNP. The blood BNP test allows accurate estimation of coronary functions....
... immunosorbent assay method for the semi-quantitative ... myeloperoxidase in human serum. The results ... used as an aid in the ... conditions associated with elevated anti-neutrophil cytoplasmic ...
... The determination of Ang II ... monitoring the pharmacological effect and ... of angiotensin converting enzyme inhibitors ... receptor antagonists as well as ...
Medicine Products: